(1-乙基-4-哌啶基)甲胺 | 21168-71-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: (1-乙基-4-哌啶基)甲胺
• 中文别名: N-乙基-4-氨甲基哌啶；(1-乙基哌啶-4-基)甲胺
• 英文名称: <(1-ethyl-4-piperidyl)methyl>amine
• 英文别名: (1-ethylpiperidin-4-yl)methanamine；(1-ethylpiperidin-4-yl)methylamine；C-(1-ethyl-piperidin-4-yl)-methylamine；C-(1-Ethyl-piperidin-4-yl)-methylamine；(1-ethylpiperidine-4-yl)methanamine；1-ethyl-4-aminomethylpiperidine
• CAS: 21168-71-8
• 化学式: C₈H₁₈N₂
• mdl: MFCD05022431
• 分子量: 142.244
• InChiKey: ZLODGCYXZYPQKQ-UHFFFAOYSA-N

物化性质

• 沸点：
  87 °C
• 密度：
  0.889±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Name:	(1-Ethyl-4-piperidinyl)methanamine Material Safety Data Sheet
Synonym:	None Known
CAS:	21168-71-8

Section 1 - Chemical Product MSDS Name:(1-Ethyl-4-piperidinyl)methanamine Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
21168-71-8	(1-Ethyl-4-piperidinyl)methanamine	97+	unlisted

Hazard Symbols: C
Risk Phrases: 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Causes burns.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Chronic exposure may cause effects similar to those of acute exposure.

---

Section 4 - FIRST AID MEASURES
Eyes: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. Get medical aid immediately.
Skin:
In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Get medical aid immediately. Wash clothing before reuse.
Ingestion:
If swallowed, do NOT induce vomiting. Get medical aid immediately.
If victim is fully conscious, give a cupful of water. Never give anything by mouth to an unconscious person.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If breathing is difficult, give oxygen. Do NOT use mouth-to-mouth resuscitation.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container. Avoid runoff into storm sewers and ditches which lead to waterways. Clean up spills immediately, observing precautions in the Protective Equipment section. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Keep container tightly closed. Do not ingest or inhale. Discard contaminated shoes. Use only with adequate ventilation.
Storage:
Keep container closed when not in use. Store under an inert atmosphere.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 21168-71-8: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: colorless
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 87.5-90.1 deg C @ 6mmHg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H18N2
Molecular Weight: 142.24

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
None reported.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, oxides of nitrogen, carbon dioxide.
Hazardous Polymerization: Will not occur.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 21168-71-8 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
(1-Ethyl-4-piperidinyl)methanamine - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION
Ecotoxicity:
Fish: Pseudomonas putida:

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: AMINES, LIQUID, CORROSIVE, N.O.S.
Hazard Class: 8
UN Number: 2735
Packing Group: III
IMO
Shipping Name: AMINES, LIQUID, CORROSIVE, N.O.S.
Hazard Class: 8
UN Number: 2735
Packing Group: III
RID/ADR
Shipping Name: AMINES, LIQUID, CORROSIVE, N.O.S.
Hazard Class: 8
UN Number: 2735
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 6 Keep under nitrogen.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 21168-71-8: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 21168-71-8 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 21168-71-8 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (1-乙基-4-哌啶基)甲胺 在 盐酸 作用下， 以 1,4-二氧六环 、 氯仿 为溶剂， 反应 5.5h， 生成 N-(1-Ethylpiperidin-4-yl)methyl-2-cyclohexyl-2-hydroxy-2-phenylacetamide
  参考文献：
  名称：

  用于治疗逼尿肌过多的药物。VI。N取代基中带有环胺的乙酰胺衍生物的合成和药理特性。

  摘要：

  为了提高功效并减少奥昔布宁（1）的副作用，N-[（四氢-3-或4-吡啶基）甲基]-，N-（4-哌啶基）-和N-（3合成了-或4-哌啶基烷基）-2-羟基乙酰胺（3a-n​​，4a-g）和相关的羧酰胺（3o-r，4h-k，13'，17）并评估了其对膀胱节律性收缩的抑制活性大鼠和散瞳活动的大鼠。这些化合物中的一些在对膀胱收缩的抑制活性和对膀胱收缩的抑制活性与散瞳活性之间的选择性方面均优于奥昔布宁。其中，N-[（（1,2,3,6-四氢-4-吡啶基）甲基]-和N-[（1,2,3,6-四氢-1-甲基-4-吡啶基）甲基]- 2-羟基-2,2-二苯基乙酰胺（3e，3f）对膀胱收缩表现出最有效的抑制活性（ED30 = 0。静脉注射分别为005和0.003 mg / kg）。从3e对豚鼠体外逼尿肌收缩的影响来看，似乎3e体内抑制膀胱收缩的活性主要与卡巴胆碱诱导的体外对逼尿肌收缩的抑制活性有关（类抗毒蕈碱活性）。

  DOI：

  10.1248/cpb.42.74
• 作为产物：
  描述：

  1-(4-(氨基甲基)哌啶-1-基)乙酮 在 sodium hydroxide 作用下， 以 四氢呋喃 、 水 为溶剂， 生成 (1-乙基-4-哌啶基)甲胺
  参考文献：
  名称：

  Indoles

  摘要：

  一种由以下公式表示的1,4-取代的环胺衍生物或其药理学上可接受的盐： 其中A、B、C、D、T、Y和Z分别表示亚甲基或氮键合物；R1、R2、R3、R4和R5分别表示取代基；n表示0或1至3的整数；m表示0或1至6的整数；p表示1至3的整数。这些化合物具有5-羟色胺拮抗作用。因此，在临床上作为药物特别有用，用于治疗、改善和预防痉挛性瘫痪。它们还可用作中枢肌肉松弛剂，改善肌张力过高。

  公开号：

  US20020019531A1

文献信息

• Synthesis and antimalarial effects of N2-aryl-N4-[(dialkylamino)alkyl]- and N4-aryl-N2-[(dialkylamino)alkyl]-2,4-quinazolinediamines
  作者：Edward F. Elslager、Carolyn Hess、Judith Johnson、Daniel Ortwine、Vera Chu、Leslie M. Werbel

  DOI：10.1021/jm00134a002

  日期：1981.2

  N4)-aryl-N4(and N2)-[(dialkylamino)alkyl]-2,4-quinazolinediamines has been synthesized for antimalarial evaluation. Condensation of the appropriate 2,4-dichloroquinazoline (IV) with the requisite N,N-dialkylalkylenediamine afforded a series of 2-chloro-N-[(dialkylamino)alkyl]-4-quinazolinamines (V) which were condensed with the appropriate arylamine to provide the corresponding N2-aryl-N4-[(dialkylamino)alkyl]-2

  合成了一系列的N2（和N4）-芳基-N4（和N2）-[（（二烷基氨基）烷基] -2,4-喹唑啉二胺类，用于抗疟疾评估。适当的2，4-二氯喹唑啉（IV）与必要的N，N-二烷基亚烷基二胺缩合得到一系列的2-氯-N-[（（二烷基氨基）烷基] -4-喹唑啉胺（V），其与适当的芳基胺缩合。提供相应的N 2-芳基-N 4-[（（二烷基氨基）烷基] -2，4-喹唑啉二胺（VI）。将2,4-二氯喹唑啉水解为2-氯-4-喹唑啉，然后与适当的N，N-二烷基亚烷基二胺缩合，得到2-[[[（二烷基氨基）烷基]氨基] -4-喹唑啉（IXa）阵列。用三氯氧化磷氯化并与必要的芳基胺缩合得到N2-[（（二烷基氨基）烷基] -N4-苯基-2,4-喹唑啉二胺（X）。N2-芳基-N4-[（（二烷基氨基）烷基] -2,4-喹唑啉二胺（VI）中普遍具有抗疟活性，而反向异构体的活性较低。光毒性责任排除了对该系列成员的临床评估。
• [EN] QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS<br/>[FR] DÉRIVÉS DE QUINOLONE UTILISÉS EN TANT QU'INHIBITEURS DU RÉCEPTEUR DU FACTEUR DE CROISSANCE DES FIBROBLASTES
  申请人：PRINCIPIA BIOPHARMA INC

  公开号：WO2015120049A1

  公开（公告）日：2015-08-13

  Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

  公开了作为成纤维细胞生长因子抑制剂（FGFR）的化合物，因此可用于治疗可以通过抑制FGFR治疗的疾病。还公开了含有此类化合物的药物组合物以及制备此类化合物的过程。
• [EN] BICYCLIC COMPOUND AND USE THEREOF FOR INHIBITING HISTONE METHYLTRANSFERASE<br/>[FR] COMPOSÉ BICYCLIQUE ET SON UTILISATION POUR INHIBER L'HISTONE MÉTHYLTRANSFÉRASE
  申请人：ONCOTHERAPY SCIENCE INC

  公开号：WO2018165112A1

  公开（公告）日：2018-09-13

  The present invention relates to a compound represented by formula (I), a method for the preparation thereof, and a pharmaceutical composition containing the compound as an active ingredient for inhibiting histone methyltransferase such as SUV39H2.

  本发明涉及一种由式（I）表示的化合物，其制备方法，以及含有该化合物作为活性成分的药物组合物，用于抑制组蛋白甲基转移酶，如SUV39H2。
• New compounds
  申请人：Zahn Stephan Karl

  公开号：US20090163467A1

  公开（公告）日：2009-06-25

  The present invention encompasses compounds of general formula (1) wherein R 1 , R 2 , R 4 , X, m, n and p are defined as in claim 1 , which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use for preparing a pharmaceutical composition having the above-mentioned properties.

  本发明涵盖了一般式（1）的化合物 其中 R 1 ，R 2 ，R 4 ，X，m，n和p的定义如权利要求书中所述 ，适用于治疗以细胞过度或异常增殖为特征的疾病，并且用于制备具有上述特性的药物组合物。
• PYRROLOTRIAZINE KINASE INHIBITORS
  申请人：Fink E. Brian

  公开号：US20080045496A1

  公开（公告）日：2008-02-21

  The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of such as TrkA, TrkB, TrkC, Jak2, Jak3 and CK2, thereby making them useful as antiproliferative agents for the treatment of cancer and other diseases.

  本发明提供了公式I的化合物以及药用可接受的盐类。公式I的化合物可以抑制诸如TrkA、TrkB、TrkC、Jak2、Jak3和CK2的酪氨酸激酶活性，从而使其作为抗增殖剂用于治疗癌症和其他疾病的有用性。